Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 8.01, 9.01 · 8-K

Quest Diagnostics Inc.

DGXNYSEEQUITYCurrent

Other Events

Item 8.01 Other Events On April 27, 2026, Quest Diagnostics Incorporated (the “Company”) issued a press release announcing the pricing of a public offering of $500 million aggregate principal amount of its 5.000% senior notes due 2036 (the “Notes”) under the Company’s shelf registration statement.…

Filed May 1, 2026Accepted May 1, 2026, 4:15 PM EDTCIK 1022079Accession 0001104659-26-054141
Share

Company context

Quest Diagnostics works across healthcare to create a healthier world, one life at a time. We help connect people, from clinicians to consumers, with laboratory insights that illuminate a path to better health. With a focus on delivering smarter, simpler testing, our insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics serves half the physicians and hospitals in the United States and one in three adult Americans each year, and our nearly 60,000 employees work together to deliver diagnostic insights that inspire actions to transform lives. www. QuestDiagnostics.com.

Current securities

Recent company filings

  1. SCHEDULE 13G - filed by STATE STREET CORP regarding QUEST DIAGNOSTICS INCNov 10, 2026
  2. 10-Q filingOct 23, 2026
  3. Other EventsOct 22, 2026
  4. Results of Operations and Financial ConditionOct 22, 2026
  5. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsOct 6, 2026

Registered securities in this filing

Quest Diagnostics Incorporated · 8-K · Filed 2026-05-01

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, $0.01 Par Value

Symbol
DGX
Exchange
NYSE
Classification
COMMON
Status
Current
Filing context

Context: AsOf2026-04-27

Dimensions: Not supplied

Accession 000110465926054141 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 8.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events On April 27, 2026, Quest Diagnostics Incorporated (the “Company”) issued a press release announcing the pricing of a public offering of $500 million aggregate principal amount of its 5.000% senior notes due 2036 (the “Notes”) under the Company’s shelf registration statement. The Company intends to use the net proceeds from the offering for general corporate purposes, which may include the repayment of indebtedness. The indebtedness the Company may repay includes its $500 million aggregate principal amount of 3.45% Senior Notes that mature on June 1, 2026. The Company expects to receive the net proceeds upon closing of the offering on May 6, 2026, subject to customary closing conditions. A copy of the press release, dated April 27, 2026, is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference into this Current Report on Form 8-K. In connection with the offering of the Notes, on April 27, 2026, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Mizuho Securities USA LLC on behalf of themselves and the other underwriters named therein. The Underwriting Agreement is attached to this Current Report on Form 8-K as Exhibit 1.1 and is incorporated by reference into this Current Report on Form 8-K.
Filed exhibits (1)
EX-99.1 (by filename) tm2613096d1_ex99-1.htm

EX-99.1 3 tm2613096d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Quest Diagnostics Prices $500 Million of Senior Notes SECAUCUS, NJ - April 27, 2026 /PRNewswire/ - Quest Diagnostics Incorporated (NYSE: DGX) (the “Company”), a leader in diagnostic information services, today announced the pricing of a public offering of $500 million aggregate principal amount of its 5.000% senior notes due 2036 (the “Notes”) under Quest Diagnostics' shelf registration statement. Quest Diagnostics expects to receive the net offering proceeds upon closing on May 6, 2026, subject to the satisfaction of customary closing conditions. The Company expects to use the net proceeds from the offering for general corporate purposes, which may include the repayment of indebtedness. The indebtedness the Company may repay with the net proceeds of this offering includes its $500 million aggregate principal amount of 3.45% Senior Notes which will mature on June 1, 2026. This press release shall not constitute an offer to sell or a solicitation of an offer to purchase any of these securities and shall not constitute an offer, solicitation or sale in any state or jurisdiction in which such an offer, solicitation or …

Open exhibit ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.